FASN and breast carcinoma: Our results lead us to propose that the PR isoform-specific regulation of distinct regulatory responses in the cross-talk between prolactin and FASN might be involved in the diverse phenotypic outcomes arising from the prolactin/PRLR signaling axis in luminal breast cancer.